BACKGROUND:Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown. METHODS: We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IVoropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer. RESULTS: The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P=0.18; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage. CONCLUSIONS: Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.) 2010 Massachusetts Medical Society
RCT Entities:
BACKGROUND:Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown. METHODS: We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer. RESULTS: The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P=0.18; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage. CONCLUSIONS:Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.) 2010 Massachusetts Medical Society
Authors: M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: K K Fu; T F Pajak; A Trotti; C U Jones; S A Spencer; T L Phillips; A S Garden; J A Ridge; J S Cooper; K K Ang Journal: Int J Radiat Oncol Biol Phys Date: 2000-08-01 Impact factor: 7.038
Authors: Boudewijn J M Braakhuis; Peter J F Snijders; Willem-Jan H Keune; Chris J L M Meijer; Henrique J Ruijter-Schippers; C René Leemans; Ruud H Brakenhoff Journal: J Natl Cancer Inst Date: 2004-07-07 Impact factor: 13.506
Authors: David Lindquist; Mircea Romanitan; Lalle Hammarstedt; Anders Näsman; Hanna Dahlstrand; Johan Lindholm; Liselotte Onelöv; Torbjörn Ramqvist; Weimin Ye; Eva Munck-Wikland; Tina Dalianis Journal: Mol Oncol Date: 2007-09-01 Impact factor: 6.603
Authors: Kathleen Settle; Marshall R Posner; Lisa M Schumaker; Ming Tan; Mohan Suntharalingam; Olga Goloubeva; Scott E Strome; Robert I Haddad; Shital S Patel; Earl V Cambell; Nicholas Sarlis; Jochen Lorch; Kevin J Cullen Journal: Cancer Prev Res (Phila) Date: 2009-07-29
Authors: Shahnaz Begum; Maura L Gillison; M Ali Ansari-Lari; Keerti Shah; William H Westra Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: David J Adelstein; Yi Li; George L Adams; Henry Wagner; Julie A Kish; John F Ensley; David E Schuller; Arlene A Forastiere Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Michael R Evans; Claire D James; Molly L Bristol; Tara J Nulton; Xu Wang; Namsimar Kaur; Elizabeth A White; Brad Windle; Iain M Morgan Journal: J Virol Date: 2019-02-05 Impact factor: 5.103
Authors: Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tân; David I Rosenthal; Randal S Weber; Louise Lambert; Andy M Trotti; William L Barrett; Wade L Thorstad; Christopher U Jones; Sue S Yom; Stuart J Wong; John A Ridge; Shyam S D Rao; James A Bonner; Eric Vigneault; David Raben; Mahesh R Kudrimoti; Jonathan Harris; Quynh-Thu Le; Maura L Gillison Journal: J Clin Oncol Date: 2017-08-04 Impact factor: 44.544
Authors: Phuc Felix Nguyen-Tan; Qiang Zhang; K Kian Ang; Randal S Weber; David I Rosenthal; Denis Soulieres; Harold Kim; Craig Silverman; Adam Raben; Thomas J Galloway; André Fortin; Elizabeth Gore; William H Westra; Christine H Chung; Richard C Jordan; Maura L Gillison; Marcie List; Quynh-Thu Le Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: Alice L Tang; Samantha J Hauff; John H Owen; Martin P Graham; Michael J Czerwinski; Jung Je Park; Heather Walline; Silvana Papagerakis; Jay Stoerker; Jonathan B McHugh; Douglas B Chepeha; Carol R Bradford; Thomas E Carey; Mark E Prince Journal: Head Neck Date: 2011-12-13 Impact factor: 3.147
Authors: Gypsyamber Dʼsouza; Thomas E Carey; William N William; Minh Ly Nguyen; Eric C Ko; James Riddell; Sara I Pai; Vishal Gupta; Heather M Walline; J Jack Lee; Gregory T Wolf; Dong M Shin; Jennifer R Grandis; Robert L Ferris Journal: J Acquir Immune Defic Syndr Date: 2014-04-15 Impact factor: 3.731
Authors: V Budach; E-T Becker; D Boehmer; H Badakhshi; U Jahn; K-D Wernecke; C Stromberger Journal: Strahlenther Onkol Date: 2013-12-11 Impact factor: 3.621
Authors: Tobin Strom; Louis B Harrison; Anna R Giuliano; Michael J Schell; Steven A Eschrich; Anders Berglund; William Fulp; Ram Thapa; Domenico Coppola; Sungjune Kim; Jessica Frakes; John Foekens; James J Mulé; Javier F Torres-Roca Journal: Eur J Cancer Date: 2017-08-29 Impact factor: 9.162
Authors: Van K Morris; Asif Rashid; Miguel Rodriguez-Bigas; Prajnan Das; George Chang; Aki Ohinata; Jane Rogers; Christopher Crane; Robert A Wolff; Cathy Eng Journal: Oncologist Date: 2015-09-17